PHARMACO-ECONOMICBENEFITS OF CORRECTION OF ANEMIA WITH CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR:HEMODIALYSIS VSHEMODIAFILTRATION

V. Novakivskyy

doi:10.31450/ukrjnd.1(53).2017.04

V. Novakivskyy LLC «Fresenius Medical Care Ukraine» Medical Centre

DOI: https://doi.org/10.31450/ukrjnd.1(53).2017.04

Keywords: anemia, hemoglobin, hemodialysis, hemodiafiltration, continuous erythropoiesis receptor activator

Abstract

Anemia is an integral component of CKD. The prescribing of erythropoiesis stimulating agents (ESA) for the treatment of anemia constitutes a significant burden on health budgets. Using of continuous erythropoietin receptor activator (CERA) and convective techniques can improve health indicators and economic results.

The aim of the study was to evaluate the effects of hemodiafiltration treatment (HDF) on the pharmaco-economic efficiency of anemia treatment in comparison with haemodialysis (HD).

Methods. A prospective cross-sectional study involving 40 patients with CKD stage V who receiving dialysis treatment at the LLC “Fresenius Medical Care Ukraine ” Medical center in Cherkasy city. The follow-up period was 2 years. First, data was analyzed while patients received HD over a period of twelve months. Then, the same patients were evaluated during treatment with HDF for at least another twelve months.

Result. The average dose of CERA reduced from 60 mg to 44 mg per month (p = 0.002) after the transferred ofpatients to HDF treatment. There were a significantly increased the levels of Kt / V (p = 0.04) and serum albumin (p = 0.04). A higher number of patients achieved the target hemoglobin results.

Conclusions. The comparison of pharmaco-economic component of anemia correction with CERA cross-sectional study demonstrates significant advantages of HDF treatment compared to HD.

Downloads

Download data is not yet available.

References

Реброва О. Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA / О. Ю. Реброва. – М.: Медиасфера, 2003. – 312 с.

Лікування хворих на з хронічну хворобу нирок V ГД стадії. Адаптована клінічна настанова, заснована на доказах та уніфіковані клінічні протоколи. – К. : «Поліграф плюс», 2016. – 228 с.

Aggarwal H. K. Efficacy and safety of continuous erythorpoietin receptor activator (C.E.R.A) in patients of chronic renal failure with anemia / Aggarwal H. K., Jain D., Verma K. // Int. J Pharm Pharm Sci. - 2011. - V. 3. - P. 292-297.

Carole Ayav. Competing risk of death and endstage renal disease in incident chronic kidney disease (stages 3 to 5): the EPIRAN community-based study / Carole Ayav, Jean-Baptiste Beuscart, Serge Briançon, Alain Duhamel, Luc Frimat, [et al.] // BMC Nephrol. - 2016. - V. 17. - P. 174.

Charalampos Loutradis. Diabetes mellitus increases the prevalence of anemia in patients with chronic kidney disease: A nested case-control study / Charalampos Loutradis, Alexandra Skodra, Panagiotis Georgianos, Panagiota Tolika [et al] // World J Nephrol. - 2016. - V. 6; 5(4). - P. 358-366.

Krick G. On-Line Hemodiafiltration The Journey and the Vision / G.Krick, C.Ronco // Contributions to Nephrology - KARGER, 2011. - V.175.

Locatelli F. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement / Locatelli F., Barany P., Covic A., De Francisco A., [et al.] // Nephrol Dial Transplant. - 2013. - V. 28. - P. 1346-1359.

Locatelli F. Erythropoiesis-stimulating agents in renal medicine / Locatelli F., Del Vecchio L. // Oncologist. - 2011. - V. 16 (Suppl 3). - P. 19-24.

Locatelli F. Management of anaemia by convective treatments / Locatelli F., Manzoni C., Del Vecchio L., [et al.] // Contrib Nephrol, Basel Karger. - 2011. -V. 168. - P. 162-172.

Locatelli F. Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a multicentre randomized and controlled trial / Locatelli F., Altieri P., Andrulli S., [et al.] // Nephrology Dialysis Transplantation. - 2012. - V. 27(9). - P. 3594-3600.

Macdougall I. C. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (CERA) in patients with chronic kidney disease / Macdougall I. C., Robson R., Opatrna S., Liogier X., Pannier A., [et al.] // Clin J Am Soc Nephrol. - 2006. - V. 1. - P. 1211-1215.

National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. / AJKD. - 2012. - V. 60. - P. 850-886.

Ohashi N. Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease / Ohashi N., Sakao Y., Yasuda H., Kato A., Fujigaki Y. // Int J Nephrol Renov Dis. - 2012. - V. 5. - P. 53-60.

Panichi V. Anaemia and resistance to erythropoie- sis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study / Panichi V., Rosati A., Bigazzi R., [et al.] // Nephrol Dial Transplant. – 2011. – V. 26. – P. 2641-2648.

Roche. Mircera (methoxy polyethylene glycol-epoetin beta) – Product Information, 2011.

Sang-Ryol Ryu. The Prevalence and Management of Anemia in Chronic Kidney Disease Patients: Result from the Korea N Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) / Sang-Ryol Ryu, Sue K. Park, Ji Yong Jung, [et al.] // J Korean Med Sci. – 2017. – V. 32(2). - P. 249-256.